GlobalData (LSE:DATA), the data, insight and technology company, expects first-half revenue to grow approximately 3%, including underlying revenue growth of around 1%, against a backdrop of elongated sales cycles it described as industry-wide.
Adjusted EBITDA for the six months to 30 June is expected to grow 4% to 5% on the prior year, though the group guided full-year adjusted EBITDA to the low end of its compiled consensus range of £126m to £134m, reflecting planned second-half actions to accelerate margin.
Contracted forward revenue growth came in at approximately 6%, with underlying growth of 1%.
Both divisions contributed equally: the Non-Healthcare unit delivered underlying revenue growth of around 1%, while Healthcare matched that figure, though Healthcare's contracted forward revenue declined 1%, reflecting pressure in the pharmaceuticals market.
Value renewal rates held at approximately 89%, broadly in line with the 88% recorded at December 2025.
The group also announced the acquisition of Cambridge Healthcare, a bolt-on deal within its Healthcare division targeting the pharmaceuticals competitive intelligence market, with a material EBITDA contribution expected from 2027.
GlobalData intends to launch a £30m tender offer on 10 July, taking total capital returns for the year to £45m, plus £8m carried over from 2025 programmes; the group also upsized its non-Healthcare credit facility by £60m to £245m.
"The board believes that the sum-of-the-parts value of the group's portfolio has the potential to be much greater than the group's current market capitalisation," chief executive Mike Danson said.
Full half-year results are scheduled for 14 September, when the board will set out the next stage of its value creation plan.
